UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`v.
`ADAPT PHARMA OPERATIONS LIMITED, AND
`OPIANT PHARMACEUTICALS, INC.
`Patent Owners.
`_____________________
`
`CASE IPR2019-00688
`U.S. Patent No. 9,468,747
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`v.
`ADAPT PHARMA OPERATIONS LIMITED, AND
`OPIANT PHARMACEUTICALS, INC.
`Patent Owners.
`_____________________
`
`CASE IPR2019-00688
`U.S. Patent No. 9,468,747
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`I.
`
`IPR2019-00688 – U.S. Patent No. 9,468,747
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1)
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies that Nalox-1
`
`Pharmaceuticals, LLC, BCIM Partners III, LP, BCIM General Partner III, LP,
`
`Burford Capital Ireland DAC, BCIM PIII Holdings, LLC, Burford Capital
`
`Investment Management LLC, Burford Capital Holdings (UK) Limited, and Burford
`
`Capital Limited are the real parties in interest (collectively, “RPI”), and remains
`
`unchanged since Petitioner’s prior mandatory notices. Nalox-1 Pharmaceuticals,
`
`LLC, a Delaware limited liability company, is 100% owned by BCIM Partners III,
`
`LP, a Delaware limited partnership. BCIM General Partner III, LLC, a Delaware
`
`limited liability company, is the general partner of BCIM Partners III, LP, and
`
`Burford Capital Investment Management LLC is the investment manager to BCIM
`
`Partners III, LP. No other person has authority to direct or control (i) the timing of,
`
`filing of, content of, or any decisions or other activities relating to this Petition or
`
`(ii) any timing, future filings, content of, or any decisions or other activities relating
`
`to the future proceedings related to this Petition. All of the costs associated with this
`
`Petition are expected to be borne by Nalox-1 Pharmaceuticals, LLC, BCIM Partners
`
`III, LP, BCIM General Partner III, LP, Burford Capital Investment Management
`
`LLC and Burford Capital Holdings (UK) Limited.
`
`II. Related Matters Under 37 C.F.R. § 42.8(b)(2)
`Petitioner identifies the following judicial or administrative matters that
`
`AFDOCS/22424483.1
`
`
`
`
`IPR2019-00688 – U.S. Patent No. 9,468,747
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`would affect, or be affected by, a decision in this proceeding: claims 7 and 9 of U.S.
`
`Patent No. 9,468,747; claim 4 of U.S. Patent No. 9,561,177; claims 21, 24, and 25
`
`of U.S. Patent No. 9,629,965; and claims 2, 24, 33, and 38 of U.S. Patent No.
`
`9,775,838 have all been held invalid in a case captioned Adapt Pharma Operations
`
`Ltd. et al. v. Teva Pharmaceuticals USA, Inc., C.A. No. 16-cv-7721 in the U.S.
`
`District Court for the District of New Jersey (Jun. 5, 2020). Petitioner is not a party
`
`to this action. Petitioner has filed inter partes review petitions (which have been
`
`instituted) on related U.S. Patent Nos. 9,211,253 and 9,629,965, which are listed in
`
`The Orange Book as covering Narcan® nasal spray (naloxone).
`
`III.
`
`Identification of Lead and Back-Up Counsel Under 37 C.F.R. §
`42.8(b)(3)
`
`Petitioner provides the following designation of counsel:
`
`Lead Counsel
`
`
`Dr. Yelee Y. Kim (Reg. No. 60,088)
`Telephone: 202.857.6147
`Fax: 202.857.6395
`Yelee.Kim@arentfox.com
`
`
`
`Back-Up Counsel
`
`
`Janine A. Carlan (Reg. No. 42,387)
`Telephone: 202.715.8506
`Fax: 202.857.6395
`Janine.Carlan@arentfox.com
`
`Richard Berman (Reg. No. 39,107)
`Telephone: 202.857.6232
`Fax: 202.857.6395
`Richard.Berman@arentfox.com
`
`Bradford Frese (Reg. No. 69,772)
`Telephone: 202.857.6496
`Fax: 202.857.6395
`Bradford.Frese@arentfox.com
`
`
`AFDOCS/22424483.1
`
`
`
`
`IPR2019-00688 – U.S. Patent No. 9,468,747
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`
`Lead Counsel
`
`Back-Up Counsel
`Christopher Yaen (Reg. No. 66,563)
`Telephone: 202.350.3760
`Fax: 202.857.6395
`Christopher.Yaen@arentfox.com
`
`
`IV. Service Information Under 37 C.F.R. § 42.8(b)(4)
`
`Please address all correspondence to above-identified counsel at:
`
`ARENT FOX LLP
`1717 K Street NW
`Washington D.C. 20006
`Petitioner consents to electronic service.
`
`
`
`Date: June 26, 2020
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`/s/ Yelee Y. Kim
`Yelee Y. Kim, Reg. No. 60,088
`ARENT FOX LLP
`1717 K Street, NW
`Washington, DC 20006
`202.857.6000
`Counsel for Petitioner
`Nalox-1 Pharmaceuticals, LLC
`
`
`AFDOCS/22424483.1
`
`
`
`
`
`
`IPR2019-00688 – U.S. Patent No. 9,468,747
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))
`The undersigned hereby certifies that the above-captioned “Petitioner’s
`
`Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8” was served in its entirety
`
`on June 26, 2020, upon the following parties via e-mail:
`
`Jessamyn S. Berniker (jberniker@wc.com)
`Ana C. Reyes (areyes@wc.com)
`David M. Krinsky (dkrinsky@wc.com)
`Anthony H. Sheh (asheh@wc.com)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, NW
`Washington, DC 20005
`(202) 434-5000
`Counsel for Patent Owner
`Adapt Pharma Operations Limited
`
`Jessica Tyrus Mackay (jmackay@greengriffith.com)
`Ann K. Kotze (akotze@greengriffith.com)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`/s/ Yelee Y. Kim
`Yelee Y. Kim, Reg. No. 60,088
`ARENT FOX LLP
`1717 K Street, NW
`Washington, D.C. 20006
`(202) 857-6000
`yelee.kim@arentfox.com
`
`
`
`Counsel for Petitioner
`Nalox-1 Pharmaceuticals, LLC
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`AFDOCS/22424483.1
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
